ImmunityBio, Inc.
IBRX • NASDAQ
ImmunityBio, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Richard Gerald Adcock, with a market cap of $7.6B.
CEORichard Gerald Adcock
Next Earnings
Upcoming earnings announcement for ImmunityBio, Inc.
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (6:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.07
Revenue Estimate
$42.3M
Earnings History
Past 12 earnings reports for ImmunityBio, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 23, 2026 | Q4 2025 | -$0.06Est: -$0.09 | +33.3% | $38.3MEst: $37.5M | +2.1% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$0.07Est: -$0.10 | +30.0% | $32.1MEst: $31.0M | +3.4% | 10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.10Est: -$0.10 | 0.0% | $26.4MEst: $25.0M | +5.7% | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.15Est: -$0.14 | -7.1% | $16.5MEst: $17.5M | -5.6% | 10-Q |
| Mar 3, 2025 | Q4 2024 | -$0.09Est: -$0.26 | +65.4% | $7.6MEst: $8.7M | -13.6% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.14Est: -$0.17 | +17.6% | $6.1MEst: $4.4M | +40.0% | 10-Q |
| Aug 12, 2024 | Q2 2024 | -$0.20Est: -$0.17 | -17.6% | $1.0MEst: $2.5M | -58.5% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.20Est: -$0.16 | -25.0% | $40.0KEst: $20.0K | +100.0% | 10-Q |
| Mar 19, 2024 | Q4 2023 | -$0.38Est: -$0.18 | -111.1% | $139.0KEst: $20.0K | +595.0% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$0.19Est: -$0.27 | +29.6% | $82.0KEst: $30.0K | +173.3% | — |
| Aug 8, 2023 | Q2 2023 | -$0.32Est: -$0.23 | -39.1% | $41.0K | — | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.27Est: $0.00 | — | $360.0KEst: $360.0K | 0.0% | — |